[0015] In additional aspects of the disclosure, methods of accelerating emergence from anesthesia, or countering the effects of anesthesia, including reversing the effects of anesthesia, are provided comprising administering to a patient undergoing a medical procedure with an anesthesia agent a pharmaceutically effective amount of a composition of the disclosure.

[0016] In still further aspects of the disclosure, use of a pharmaceutically effective amount of a composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid and glutamic acid for treating a host mammal undergoing a medical procedure with an anesthesia agent is provided.

[0016a] In one aspect, there is provided a use of the composition as described herein in the manufacture of a medicament for accelerating emergence from anesthesia or countering the effects of anesthesia wherein the composition is to be administered to a patient undergoing a medical procedure with an anesthesia agent.

[0017] In yet additional aspects of the disclosure, use of a pharmaceutically effective amount of a composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid and glutamic acid for accelerating emergence from anesthesia or countering the effects of anesthesia, including reversing the effects of anesthesia, in a host mammal is provided.

[0017a] In another aspect, there is provided a use of the composition described herein in the manufacture of a medicament for treating a patient suffering from opioid intoxication or overdose wherein the composition is to be administered to the patient.

[0018] In still further aspects of the disclosure, kits comprising caffeine, sodium benzoate, one or more of lactic acid, acetic acid, aspartic acid and glutamic acid, and optionally water are provided.

[0019] In additional aspects of the disclosure, stable compositions are provided.

[0020] In further aspects of the disclosure, methods of treating patients who suffer from opioid toxicity or overdose comprising treating a patient in need thereof with a pharmaceutically effective amount of a composition of the disclosure are provided.

[0021] In still further aspects of the disclosure, use of a pharmaceutical composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid and glutamic acid for treating a host mammal undergoing treatment for opioid toxicity or overdose is provided.

[0022] More embodiments are included in the detailed description that follows.

DETAILED DESCRIPTION

[0023] Various additional embodiments of the disclosure will now be explained in further detail. Both the foregoing general description and the following detailed description are exemplary and explanatory only, and are not restrictive of this disclosure or of the claims. Any discussion of certain embodiments or features, including those depicted in the

CLAIMS:

1. A composition comprising caffeine, sodium benzoate, and one or more of lactic acid, acetic acid, aspartic acid and glutamic acid.

2. The composition of claim 1, further comprising water.

3. The composition of claim 2, wherein the composition is in the form of a solution.

4. The composition of any one of claims 1-3, which comprises lactic acid.

5. The composition of any one of claims 1-4, wherein the molar ratio of caffeine to sodium benzoate is from about 1:1.0 to about 1:1.5.

6. The composition of any one of claims 1-5, wherein the molar ratio of caffeine to the total moles of lactic acid, acetic acid, aspartic acid and glutamic acid is from about 1:0.1 to about 1:0.3.

7. The composition of any one of claims 1-6, wherein the molar ratio of sodium benzoate to the total moles of lactic acid, acetic acid, aspartic acid and glutamic acid is from about 1:0.15 to about 1:0.18.

8. The composition of claim 3, wherein the pH of the composition is from about 5 to about 6.

9. The composition of claim 2, wherein the solubility of the caffeine is 240 mg/ml or greater.

10. The composition of claim 2, wherein the weight percent of caffeine is from about 15% to about 25%, the weight percent of sodium benzoate is from about 15% to about 25%, the weight percent of lactic acid is from about 1% to about 3%, and the weight percent of water is from about 50% to about 70%.

11. The composition of claim 4,

wherein the composition is in the form of an aqueous solution;

wherein the molar ratio of caffeine to sodium benzoate is from about 1:1.3 to about 1:1.45;

wherein the molar ratio of sodium benzoate to lactic acid is from about 1:0.15 to about 1:0.18; and

wherein the solubility of the caffeine in the aqueous solution is 250 mg/mL or greater.

12. The composition of any one of claims 2-11, wherein the composition is heat stable when subjected to a temperature of 135 ºC for 45 minutes.

13. A pharmaceutical composition comprising a composition of any one of claims 1-12 and one or more pharmaceutically acceptable excipients.

14. Use of the composition of any one of claims 1 to 13 in the manufacture of a medicament for accelerating emergence from anesthesia or countering the effects of anesthesia wherein the composition is to be administered to a patient undergoing a medical procedure with an anesthesia agent.

15. A parenteral pharmaceutical composition comprising a composition of any one of claims 1-13.

16. The parental pharmaceutical composition of claim 15, which is configured for intramuscular or subcutaneous routes.

17. Use of the composition of any one of claims 1 to 13 in the manufacture of a medicament for treating a patient suffering from opioid intoxication or overdose wherein the composition is to be administered to the patient.